Trade Verve Therapeutics, Inc. - VERV CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.05 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023485% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001262% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 4.52 |
| Open | 4.32 |
| 1-Year Change | -67.45% |
| Day's Range | 4.08 - 4.34 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Mar 31, 2025 | 4.52 | -0.47 | -9.42% | 4.99 | 4.99 | 4.52 |
| Mar 28, 2025 | 5.19 | -0.01 | -0.19% | 5.20 | 5.34 | 5.12 |
| Mar 27, 2025 | 5.26 | -0.13 | -2.41% | 5.39 | 5.39 | 5.16 |
| Mar 26, 2025 | 5.37 | -0.39 | -6.77% | 5.76 | 5.79 | 5.28 |
| Mar 25, 2025 | 5.82 | 0.02 | 0.34% | 5.80 | 5.85 | 5.44 |
| Mar 24, 2025 | 5.75 | 0.14 | 2.50% | 5.61 | 5.97 | 5.57 |
| Mar 21, 2025 | 5.51 | 0.17 | 3.18% | 5.34 | 5.59 | 5.25 |
| Mar 20, 2025 | 5.51 | -0.10 | -1.78% | 5.61 | 5.89 | 5.38 |
| Mar 19, 2025 | 5.86 | 0.10 | 1.74% | 5.76 | 5.89 | 5.61 |
| Mar 18, 2025 | 5.75 | -0.40 | -6.50% | 6.15 | 6.15 | 5.75 |
| Mar 17, 2025 | 6.29 | 0.35 | 5.89% | 5.94 | 6.39 | 5.77 |
| Mar 14, 2025 | 5.95 | -0.19 | -3.09% | 6.14 | 6.31 | 5.88 |
| Mar 13, 2025 | 6.13 | -0.24 | -3.77% | 6.37 | 6.57 | 5.97 |
| Mar 12, 2025 | 6.40 | 0.23 | 3.73% | 6.17 | 6.58 | 6.16 |
| Mar 11, 2025 | 6.14 | 0.28 | 4.78% | 5.86 | 6.20 | 5.55 |
| Mar 10, 2025 | 5.92 | -0.57 | -8.78% | 6.49 | 6.65 | 5.60 |
| Mar 7, 2025 | 6.69 | 0.30 | 4.69% | 6.39 | 6.78 | 6.25 |
| Mar 6, 2025 | 6.60 | 0.33 | 5.26% | 6.27 | 6.63 | 5.98 |
| Mar 5, 2025 | 6.52 | 0.39 | 6.36% | 6.13 | 6.55 | 5.88 |
| Mar 4, 2025 | 6.10 | 0.24 | 4.10% | 5.86 | 6.14 | 5.66 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Verve Therapeutics, Inc. Company profile
About Verve Therapeutics Inc
Verve Therapeutics, Inc. is a genetic medicines company. The Company is engaged in pioneering a new approach to the care of cardiovascular disease (CVD) transforming treatment from chronic management to single-course gene editing medicines. It is advancing a pipeline of single-course in vivo gene editing programs, each designed to mimic natural disease resistance mutations and turn off specific genes to lower blood lipids. The Company's initial two programs focuses on PCSK9 and ANGPTL3, two genes that regulate levels of blood lipids. Its pipeline of in vivo gene editing programs for atherosclerotic cardiovascular disease (ASCVD) includes VERVE-101 and ANGPTL3. The Company's lead product candidate, VERVE-101, is designed to be a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. Its second program is designed to permanently turn off the ANGPTL3 gene in the liver. ANGPTL3 is a key regulator of cholesterol and triglyceride metabolism.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Verve Therapeutics Inc revenues was not reported. Net loss increased from $45.7M to $120.3M. Higher net loss reflects Fair Value of antidilution rights increase from $5.4M to $25.6M (expense), Fair Value Adjustment of success payment increase from $2.4M to $7.8M (expense), Interest Income - Non Bank decrease of 12% to $142K (income).
| Industry: | Biotechnology & Medical Research (NEC) |
201 Brookline Avenue
Suite 601
BOSTON
MASSACHUSETTS 02215
US
News
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025
Coffee price forecast: 2025-2030 third-party coffee target
Coffee prices have cooled considerably in the past few months. Is a rebound in store or will they continue to fall?
09:42, 12 March 2025
The Simpsons predicted XRP to hit $589: Has the show got it right again?
Did the animated TV show predict a breakout for the XRP cryptocurrency?
11:00, 11 March 2025
Rolls-Royce share price forecast: third- party price target
Our Rolls-Royce share price forecast looks at the outlook for the FTSE 100-listed engineering company after a tough few years.
14:58, 10 March 2025
Gasoline petrol price forecast 2025-2030: Third-party price target
Discover third-party gasoline (petrol) price predictions for 2025 and beyond, with analyst targets, historical prices, and trading strategies.
10:27, 3 March 2025
USD forecast - third party data round up
The DXY hit a seven-month low in January, just a few months after a multi-decade peak in late September.
10:02, 27 February 2025
Microsoft Stock Price Forecast for 2025 and beyond: Third party price target
We assess the likely level of the Microsoft stock price in 5 years, and possible drivers behind the stock’s past performance. Read on...
18:29, 7 February 2025People also watch
Still looking for a broker you can trust?
Join the 710,000+ traders worldwide that chose to trade with Capital.com